Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02382640 · ClinicalTrials.gov registry record · Phase 1
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02382640 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 36 participants.
The verdict
NCT02382640, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
Interventions
- DRUG Febuxostat XR
- DRUG Maalox Advance Regular Strength liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02382640
The ClinicalTrials.gov registry entry for NCT02382640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Febuxostat XR is the first listed.
NCT02382640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02382640 about?
NCT02382640 is a clinical study titled "Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule". The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
What is the current status of trial NCT02382640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2015-03. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02382640?
The interventions under investigation include: Febuxostat XR (DRUG), Maalox Advance Regular Strength liquid (DRUG).
Who is sponsoring clinical trial NCT02382640?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.